ProCE Banner Activity

FORTE: Induction With Carfilzomib, Dexamethasone, and Cyclophosphamide or Lenalidomide in Newly Diagnosed MM

Slideset Download
Conference Coverage
KCd use was associated with a lower rate of nonhematologic AEs and improved odds for PBSC mobilization vs KRd use.

Released: June 07, 2017

Expiration: June 06, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology